| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
8-Epideoxyloganic acid exhibits weak pain-relief (antinociceptive) activity. As an iridoid glucoside, it may interact with pain pathways, potentially through modulation of opioid receptors, inflammatory mediators, or neurotransmitter systems involved in pain perception. The compound is also used as a quality marker for traditional Chinese medicine, suggesting it may serve as a chemical marker for the identification and standardization of herbal preparations. However, specific molecular targets have not been fully characterized.
|
|---|---|
| ln Vitro |
In vitro, 8-Epideoxyloganic acid exhibits weak antinociceptive activity. The compound has been used in laboratory studies to evaluate the quality of traditional Chinese medicine. As an iridoid glycoside, it may have additional biological activities including anti-inflammatory or antioxidant effects, though these have not been extensively characterized. The compound's weak pain-relief activity suggests it may be part of a multi-component mechanism in traditional herbal formulations.
|
| ln Vivo |
In vivo, 8-Epideoxyloganic acid exhibits weak antinociceptive activity. The compound has been studied in the context of traditional Chinese medicine quality evaluation. Its weak pain-relief effects suggest that it may contribute to the analgesic properties of herbal preparations containing this compound. However, detailed in vivo efficacy data including dose-response relationships and specific pain models are not extensively published in the available literature.
|
| Enzyme Assay |
In vitro assays for 8-Epideoxyloganic acid typically involve evaluation of antinociceptive activity using receptor binding or enzyme inhibition assays relevant to pain pathways. The compound can be analyzed by HPLC for quality control purposes in traditional Chinese medicine. Its structure can be confirmed by NMR and MS. Purity is typically assessed by HPLC with purity ≥99% available. Standard analgesic assays may be used to evaluate its activity.
|
| Cell Assay |
In vitro cellular assays for 8-Epideoxyloganic acid are not extensively documented. As an iridoid glucoside with weak antinociceptive activity, potential cellular assays could include evaluation of effects on neuronal cells or immune cells involved in pain signaling. Cytotoxicity may be assessed in relevant cell lines. The compound is typically handled as a powder and may be soluble in appropriate solvents for cell culture applications.
|
| Animal Protocol |
In vivo animal experiments for 8-Epideoxyloganic acid would typically involve rodent models of pain such as the hot plate test, tail flick test, or formalin-induced pain model, to evaluate antinociceptive activity. The compound is administered orally or intraperitoneally, and pain response latency or behavior is measured. However, detailed experimental protocols and results are not extensively published in the available literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 8-Epideoxyloganic acid are characteristic of iridoid glycosides. The compound has a molecular weight of 360.36 g/mol and molecular formula C₁₆H₂₄O₉. As a glycosylated iridoid, it is expected to have moderate to low oral bioavailability due to its hydrophilic sugar moiety. The compound may undergo deglycosylation in the gastrointestinal tract. It is typically stored as a powder at -20°C.
|
| Toxicity/Toxicokinetics |
The toxicological profile of 8-Epideoxyloganic acid is not extensively documented. As a naturally occurring iridoid glucoside found in plants used in traditional medicine, it is expected to have a relatively favorable safety profile. However, comprehensive toxicological evaluations including acute toxicity, genotoxicity, and repeated-dose studies have not been reported. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
8-Epidelologaic acid is a terpene glycoside. It has been reported to exist in Alocasia macrorrhiza, Pedicularis, and other organisms with relevant data.
8-Epideoxyloganic acid (CAS# 88668-99-9, molecular formula C₁₆H₂₄O₉, molecular weight 360.36) is a naturally occurring iridoid glucoside from Incarvillea delavayi. It exhibits weak antinociceptive activity and has been used to evaluate the quality of traditional Chinese medicine. Also known as 7-Deoxy-8-epiloganic acid. No clinical trials or regulatory approvals have been identified. |
| Molecular Formula |
C16H24O9
|
|---|---|
| Molecular Weight |
360.356366157532
|
| Exact Mass |
360.142
|
| CAS # |
88668-99-9
|
| PubChem CID |
443332
|
| Appearance |
White to off-white solid
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
597.2±50.0 °C at 760 mmHg
|
| Flash Point |
217.9±23.6 °C
|
| Vapour Pressure |
0.0±3.8 mmHg at 25°C
|
| Index of Refraction |
1.613
|
| LogP |
-0.97
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
25
|
| Complexity |
536
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1OC=C(C(=O)O)[C@H]2CC[C@H]([C@@H]12)C
|
| InChi Key |
DSXFHNSGLYXPNG-PKUPRILXSA-N
|
| InChi Code |
InChI=1S/C16H24O9/c1-6-2-3-7-8(14(21)22)5-23-15(10(6)7)25-16-13(20)12(19)11(18)9(4-17)24-16/h5-7,9-13,15-20H,2-4H2,1H3,(H,21,22)/t6-,7-,9-,10-,11-,12+,13-,15+,16+/m1/s1
|
| Chemical Name |
(1S,4aS,7R,7aR)-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.7750 mL | 13.8750 mL | 27.7500 mL | |
| 5 mM | 0.5550 mL | 2.7750 mL | 5.5500 mL | |
| 10 mM | 0.2775 mL | 1.3875 mL | 2.7750 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
